ME02191B - Protutijela koja neutraliziraju ljudski čimbenik stimuliranja kolonija makrofaga - Google Patents
Protutijela koja neutraliziraju ljudski čimbenik stimuliranja kolonija makrofagaInfo
- Publication number
- ME02191B ME02191B MEP-2015-111A MEP11115A ME02191B ME 02191 B ME02191 B ME 02191B ME P11115 A MEP11115 A ME P11115A ME 02191 B ME02191 B ME 02191B
- Authority
- ME
- Montenegro
- Prior art keywords
- set forth
- seq
- amino acid
- acid sequence
- fragment
- Prior art date
Links
- 210000003714 granulocyte Anatomy 0.000 title 1
- 210000002540 macrophage Anatomy 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 21
- 239000012634 fragment Substances 0.000 claims 11
- 239000002157 polynucleotide Substances 0.000 claims 7
- 102000040430 polynucleotide Human genes 0.000 claims 7
- 108091033319 polynucleotide Proteins 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010065159 Polychondritis Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000009169 relapsing polychondritis Diseases 0.000 claims 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000000399 orthopedic effect Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
Claims (11)
1. Ljudsko monoklonsko protutijela, ili njegov fragment, naznačeno time što sadrži:(a) varijabi lna područje lakog lanca, koje sadrži aminokiselinski slijed kao što je i znijet u SEQ ID NO: 19 i dodatno sadrži varijabi lna područje teškog lanca, koje se bira između:(i) aminokiselinskog slijeda kao što je iznijet u SEQ ID NO: 21; (ii) aminok i selinskog s lijeda kao što je iznijet u SEQ ID NO: 22; (iii)aminokise lin skog slijeda kao što je iznijet u SEQ ID NO: 52; i (iv)aminokise lin skog slijeda kao što je iznijet u SEQ ID NO: 53; ili(b)varijabilno područje l akog lanca, koje sadrži aminokiselinski slijed kao što je iznijet u SEQlD NO: 54 i dodatno sadrži varijabilna područje teškog lan ca, koje se bira između : (i) aminokiselinskog slijeda kao što je iznijet u SEQ ID NO: 23;(ii) aminokiselin skog slijeda kao što je iznijet u SEQ ID NO: 26; i(iii)aminokiselinski s lijed kao što je iznijet u SEQ ID NO: 28;ili(e) varijabi ln a područje l akog lanca, koje sadrži aminokiselinsk i slijed kao što je iznijet u SEQ ID NO: 55 i dodatno sadrži varijabi lna područje teš kog lan ca, koje se bira između:(i) aminokiselinskog slijeda kao što je iznijet u SEQ ID NO: 21; i (ii) aminokiselin skog slijeda kao što je iznijet u SEQ ID NO: 22; ili(d) laki lanac, koji sadrži aminokiselinski slijed kao što je iznijet u SEQ ID NO: 34 i dodatno sadrži teški lanac, koji se bira između:(i) aminokiselinskog slijeda kao što je iznijet u SEQ lD NO: 35; (ii) aminokiselinskog s lijeda kao što je iznijet u SEQ TD NO: 37;(iii)aminokiselinskog slijeda kao što je iznijet u SEQ ID NO: 40; (iv) aminokiselinskog slijeda kao što je iznijet u SEQ ID NO: 42; i (v) aminokiselinskog slijeda kao što je iznijet u SEQ ID NO: 48.
2. Ljudsko monoklonsko protutijela, ili njegov fragment, u skladu s patentni m zahtjevom l , naznačeno time što sadrži varijabilna područje lakog lanca, koje sadrži aminokiselinski slijed kao što je iznijet u SEQ ID NO: 19 i dodatno sadrži varijabilna područje teškog lanca, koje se bira iz aminokiselinskog slijeda kao što je iznijet u SEQ ID NO: 21 i 52.
3. Ljudsko monoklonsko protutijela, ili njegov fragment, u skladu s patentni m zahtjevom l , naznačeno time što sadrži laki lanac koji sadrži aminokiselinski slijed kao što je iznijet u SEQ ID NO: 34 i sadrži teški lanac koji sadrži aminokiselinski slijed kao što je iznijet u SEQ ID NO: 35.
4. Fragment ljudskog monoklonskog protutijela u skladu s bilo kojim od patentnih zahtjeva l do 3, naznačen time što je navedeni fragment scFv, Fv, dijatijelo, tandemno dijatijelo, Fab, Fab ' ili F(ab)2.
5. Polinukleotidna molekula, naznačena time što sadrži nukleotidni slijed koji kodira ljud sko monoklonsko protutijela, ili njegov fragment, kao što je iznijet u bilo kojem od patentnih zahtjeva 1-3.
6. Farmaceutski pripravak, naznačen time što sadrži ljudsko monoklonsko protutijela, ili njegov fragment, u skladu s bilo kojim od patentnih zahtjeva 1-4 ili polinukleotidnu molekulu u skladu s patentnim zahtjevom 5.
7. Ljudsko monoklonsko protutijela, ili njegov fragment, u skladu s bilo kojim od patentnih zahtjeva 1-4 ili polinukleotidna molekula u skladu s patentnim zahtjevom 5, naznačeni time što mogu sadržavat i jedno ili više dodatnih protuupalnih sredstava, namijenjenih upotrebi u postupku liječenja upalnih bolesti.
8. Ljudsko monoklonsko protutijela, ili njegov fragment, ili polinukleotidna molekula namijenjeni upotrebi u skladu s patentnim zahtjevom 7, naznačeni time što se navedene upalne bolesti bira iz skupine koju čine reumatoidni artritis (RA) (uključujući RA otporan na liječenje neutralizatorima TNFu), astma, multipla skleroza (MS), kronična opstruktivna plućna bolest (COPD), akutni sindrom dišnog distresa (ARDS), idiopatska plućna fibroza (IPF), upalna crijevna bolest (lBD), uveiti s, degeneracija makule, koliti s, psorijaza, Wallerova degeneracija, antifosfolipidni sindrom (APS), akutni koronarni sindrom, restenoza, ateroskleroza, recidivirajući polihondritis (RP), akutni ili kronični hepatiti s, neuspjeli ortopedski usadci , glomerulonefritis, lupus ili autoimuni poremećaji .
9. Ljudsko monoklonsko protutijela, ili njegov fragment, u skladu s bilo kojim od patentnih zahtjeva 1-4 ili polinukleotidna molekula u skladu s patentnim zahtjevom 5, naznačeni time što mogu sadržavati jedno ili više dodatnih antitumorskih sredstava, namijenjenih upotrebi u postupku liječenja tumors kih bolesti ili drugih stanja s odgođenom staničnom apoptozom , povećanim preživljenjem ili proliferacijom stanica.
10. Lj ud sko mon okl on sko protutijela, i l i njegov fragment, ili polinukl eotidna m o l ekula na mijenjeni upotrebi u s kladu s patentni m zahtjevom 9, n az načen i ti me što je naved ena tu m orska bol est rak.
11. Ljud sko mon okl on s ko protutijela, i l i njegov fragment, ili polinukl eotidna m o l ekul a namijenjeni upotrebi u skl adu s patentnim zahtjevo m l O, nazn ačen i t ime što je naved eni rak l euke mija, multipli mijel o m , ka rcin o m želuca ili karc in om kože.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05008410 | 2005-04-18 | ||
| PCT/EP2006/003528 WO2006111353A2 (en) | 2005-04-18 | 2006-04-18 | Antibody neutralizers of human granulocyte macrophage colony stimulating factor |
| EP06724392.3A EP1874819B1 (en) | 2005-04-18 | 2006-04-18 | Antibody neutralizers of human granulocyte macrophage colony stimulating factor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02191B true ME02191B (me) | 2016-02-20 |
Family
ID=37115507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-111A ME02191B (me) | 2005-04-18 | 2006-04-18 | Protutijela koja neutraliziraju ljudski čimbenik stimuliranja kolonija makrofaga |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US8017748B2 (me) |
| EP (2) | EP2468774A3 (me) |
| JP (1) | JP5085533B2 (me) |
| KR (2) | KR20150091193A (me) |
| CN (2) | CN101184777B (me) |
| AU (1) | AU2006237159B2 (me) |
| BR (1) | BRPI0608281B8 (me) |
| CA (1) | CA2605402C (me) |
| CY (1) | CY1116632T1 (me) |
| DK (1) | DK1874819T3 (me) |
| EA (2) | EA013162B1 (me) |
| ES (1) | ES2545769T3 (me) |
| HR (1) | HRP20150773T1 (me) |
| HU (1) | HUE025134T2 (me) |
| IL (2) | IL186486A0 (me) |
| ME (1) | ME02191B (me) |
| MX (1) | MX2007012569A (me) |
| NO (1) | NO344249B1 (me) |
| NZ (1) | NZ562093A (me) |
| PL (1) | PL1874819T3 (me) |
| PT (1) | PT1874819E (me) |
| RS (1) | RS54127B1 (me) |
| RU (2) | RU2458071C2 (me) |
| SG (1) | SG161292A1 (me) |
| SI (1) | SI1874819T1 (me) |
| UA (1) | UA94403C2 (me) |
| WO (1) | WO2006111353A2 (me) |
| ZA (1) | ZA200708201B (me) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA013162B1 (ru) * | 2005-04-18 | 2010-02-26 | Микромет Аг | Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека |
| JP4736037B2 (ja) | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
| CN101501070B (zh) | 2006-02-08 | 2013-12-25 | 诺福泰克公司 | 抗原性gm-csf肽和针对gm-csf的抗体 |
| US20080171038A1 (en) * | 2006-11-08 | 2008-07-17 | Kalobios Pharmaceuticals, Inc. | Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist |
| US8398972B2 (en) | 2006-11-21 | 2013-03-19 | Kalobios Pharmaceuticals, Inc. | Methods of treating dementia using a GM-CSF antagonist |
| WO2008097510A1 (en) * | 2007-02-08 | 2008-08-14 | Merck & Co., Inc. | Antibodies specific for dkk-1 |
| AU2008253608A1 (en) * | 2007-05-23 | 2008-11-27 | Crc For Asthma And Airways Ltd | Neutralizing antibodies |
| TW200918553A (en) * | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| PT2215119E (pt) | 2007-11-13 | 2013-02-11 | Boehringer Ingelheim Int | Anticorpos monoclonais que se ligam a hgm-csf e composições médicas que os compreendem |
| KR102057826B1 (ko) * | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| MX2010011761A (es) * | 2008-04-28 | 2010-11-30 | Kalobios Pharmaceuticals Inc | Anticuerpos para el factor que estimula la colonia del granulocito-macrofago. |
| KR20160117643A (ko) * | 2008-04-29 | 2016-10-10 | 암젠 리서치 (뮌헨) 게엠베하 | 치료를 위한 ｇｍ-ｃｓｆ 및 ｉｌ-17의 억제제 |
| RU2366422C1 (ru) * | 2008-05-19 | 2009-09-10 | Государственное учреждение Научно-исследовательский институт фармакологии Томского научного центра Сибирского отделения Российской Академии медицинских наук (ГУ НИИ фармакологии ТНЦ СО РАМН) | Способ коррекции депрессии гранулоцитопоэза при цитостатическом воздействии |
| ES2886063T3 (es) * | 2008-12-22 | 2021-12-16 | Univ Melbourne | Tratamiento de la artrosis |
| CN108014335A (zh) | 2008-12-22 | 2018-05-11 | 墨尔本大学 | 粒细胞巨噬细胞集落刺激因子的拮抗剂的用途 |
| BRPI1006514A2 (pt) * | 2009-05-05 | 2019-01-08 | Morphosys Ag | antagonista do gm-csf |
| SG192945A1 (en) | 2011-02-25 | 2013-09-30 | Chugai Pharmaceutical Co Ltd | Fcgriib-specific fc antibody |
| AU2012280267B2 (en) | 2011-07-06 | 2016-04-21 | Morphosys Ag | Therapeutic combinations of anti-cd20 and anti-gm-csf antibodies and uses thereof |
| WO2013090989A1 (en) | 2011-12-22 | 2013-06-27 | Csl Limited | Method of treating inflammatory bowel disease |
| WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
| JP6339578B2 (ja) | 2012-10-31 | 2018-06-06 | タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ | Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤 |
| AR093297A1 (es) | 2012-10-31 | 2015-05-27 | Amgen Res Munich Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| US20160024200A1 (en) * | 2013-03-14 | 2016-01-28 | John Schrader | Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof |
| AU2014314053C1 (en) * | 2013-08-30 | 2023-11-02 | Takeda Pharmaceutical Company Limited | Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics |
| WO2015028666A1 (en) * | 2013-08-30 | 2015-03-05 | Takeda Gmbh | Neutralizing antibody or a fragment thereof specifically binding primate gm-csf for use in the treatment and/or prevention of psoriasis |
| AU2014331667B2 (en) | 2013-10-11 | 2019-08-22 | Biomed Valley Discoveries, Inc. | TEM8 antibodies and their use |
| WO2015103549A1 (en) | 2014-01-03 | 2015-07-09 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
| AU2015257798C1 (en) * | 2014-05-07 | 2020-10-22 | Takeda Pharmaceutical Company Limited | Liquid formulation comprising GM-CSF neutralizing compound |
| EP3875481B1 (en) | 2014-11-14 | 2025-01-22 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
| WO2016079277A1 (en) * | 2014-11-21 | 2016-05-26 | Takeda Gmbh | Use of an anti-gm-csf antagonist in the treatment of an infectious disease |
| WO2016079276A1 (en) * | 2014-11-21 | 2016-05-26 | Takeda Gmbh | Use of an anti-gm-csf antagonist and an anti-ccr2 antagonist in the treatment of an infectious disease |
| US10301377B2 (en) | 2015-02-24 | 2019-05-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use |
| GB201503139D0 (en) * | 2015-02-25 | 2015-04-08 | Univ Leicester | Diagnostic and therapeutic target |
| EP3683233A1 (en) | 2015-03-20 | 2020-07-22 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Neutralizing antibodies to gp120 and their use |
| WO2017062748A1 (en) | 2015-10-07 | 2017-04-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia |
| GB201519331D0 (en) * | 2015-11-02 | 2015-12-16 | Glaxosmithkline Ip Dev Ltd | Treatment paradigm |
| CN115010805B (zh) | 2015-11-03 | 2025-01-28 | 美国政府(由卫生和人类服务部的部长所代表) | Hiv-1 gp41中和抗体及其用途 |
| WO2017192589A1 (en) | 2016-05-02 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to influenza ha and their use and identification |
| CN106872428A (zh) * | 2017-02-07 | 2017-06-20 | 远见生物科技（上海）有限公司 | 一种用于检测中性粒细胞呼吸爆发功能的试剂盒 |
| WO2018148660A1 (en) | 2017-02-10 | 2018-08-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
| CA3078349A1 (en) | 2017-10-02 | 2019-04-11 | Humanigen, Inc. | Methods of treating immunotherapy-related toxicity using a gm-csf antagonist |
| US10927168B2 (en) | 2017-10-02 | 2021-02-23 | Humanicen, Inc. | Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab |
| US10899831B2 (en) | 2017-10-02 | 2021-01-26 | Humanigen, Inc. | Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity |
| US11130805B2 (en) | 2017-10-02 | 2021-09-28 | Humanigen, Inc. | Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist |
| US11084888B2 (en) | 2017-10-24 | 2021-08-10 | ASM, Inc. | Production method for low inclusion rate polyrotaxane |
| US11976109B2 (en) | 2018-01-02 | 2024-05-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
| CA3091437A1 (en) | 2018-02-21 | 2019-08-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
| WO2020078270A1 (en) | 2018-10-15 | 2020-04-23 | Elixiron Immunotherapeutics (hong Kong) Limited | Antibodies to granulocyte-macrophage colony stimulating factor and uses thereof |
| US11078264B2 (en) | 2018-10-17 | 2021-08-03 | University Of Connecticut | Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth |
| US20220089694A1 (en) | 2018-12-20 | 2022-03-24 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof |
| EP3962523A2 (en) | 2019-05-03 | 2022-03-09 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
| US20230085439A1 (en) | 2019-05-21 | 2023-03-16 | University Of Georgia Research Foundation, Inc. | Antibodies that bind human metapneumovirus fusion protein and their use |
| EP3994173A1 (en) | 2019-07-02 | 2022-05-11 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Monoclonal antibodies that bind egfrviii and their use |
| WO2021204649A1 (en) | 2020-04-06 | 2021-10-14 | Glaxosmithkline Intellectual Property Development Limited | Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome |
| WO2022132904A1 (en) | 2020-12-17 | 2022-06-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies targeting sars-cov-2 |
| US20240117011A1 (en) | 2021-02-09 | 2024-04-11 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Antibodies targeting the spike protein of coronaviruses |
| CA3210753A1 (en) | 2021-02-09 | 2022-08-18 | University Of Georgia Research Foundation, Inc. | Human monoclonal antibodies against pneumococcal antigens |
| KR20240058167A (ko) | 2021-09-17 | 2024-05-03 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | Sars-cov-2 중화 항체 동정을 위한 합성 인간화 라마 나노바디 라이브러리 및 이의 용도 |
| EP4476251A1 (en) | 2022-02-10 | 2024-12-18 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Human monoclonal antibodies that broadly target coronaviruses |
| EP4499228A1 (en) | 2022-03-28 | 2025-02-05 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Neutralizing antibodies to hiv-1 env and their use |
| WO2024030829A1 (en) | 2022-08-01 | 2024-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind to the underside of influenza viral neuraminidase |
| WO2024054822A1 (en) | 2022-09-07 | 2024-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Engineered sars-cov-2 antibodies with increased neutralization breadth |
| WO2024064826A1 (en) | 2022-09-22 | 2024-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
| WO2024137381A1 (en) | 2022-12-19 | 2024-06-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies for treating sars-cov-2 infection |
| WO2024138155A1 (en) | 2022-12-22 | 2024-06-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Ebolavirus (sudan and zaire) antibodies from non-human primates and human vaccinees |
| WO2024243355A1 (en) | 2023-05-24 | 2024-11-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that target the rh5 complex of blood-stage plasmodium falciparum |
| AU2024296940A1 (en) | 2023-07-07 | 2026-01-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Humanized 40h3 antibody |
| AU2024300009A1 (en) | 2023-07-21 | 2026-01-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bispecific antibodies that broadly target coronaviruses |
| WO2025106427A1 (en) | 2023-11-14 | 2025-05-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv) |
| WO2025117384A1 (en) | 2023-12-01 | 2025-06-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Broadly neutralizing influenza hemagglutinin stem-directed antibodies |
| WO2025137284A2 (en) | 2023-12-21 | 2025-06-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Broadly neutralizing antibodies against sars-cov-2 and sars-cov variants |
| WO2026030473A1 (en) | 2024-07-31 | 2026-02-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | West nile virus neutralizing monoclonal antibodies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8624899D0 (en) * | 1986-10-17 | 1986-11-19 | Sandoz Ltd | Monoclonal antibodies |
| US5070013A (en) | 1988-05-31 | 1991-12-03 | Schering Corporation | Immunochemical assay for human granulocyte-macrophage colony stimulating factor |
| CA2060741A1 (en) * | 1991-02-11 | 1992-08-12 | Robert S. Greenfield | Gm-csf inhibiting oligopeptides |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| DE69834032T2 (de) | 1997-04-23 | 2006-12-07 | Universität Zürich | Verfahren zur erkennung von nucleinsäuremolekülen codierend für (poly)peptide, welche mit zielmolekülen interagieren |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| TR200003087T2 (tr) | 1998-04-21 | 2001-02-21 | Micromet Ag | Yeni CD19 X CD3 Spesifik polipeptidler ve kullanımları |
| US7157091B1 (en) * | 1999-06-18 | 2007-01-02 | Ludwig Institute For Cancer Research | MAGE-A1 peptides presented by HLA class II molecules |
| WO2001058459A1 (fr) * | 2000-02-14 | 2001-08-16 | Mitsubishi Pharma Corporation | Remedes contre l'hepatite c |
| US20050271663A1 (en) * | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| WO2003068920A2 (en) * | 2002-02-13 | 2003-08-21 | Ludwig Institute For Cancer Research | Humanized gm-csf antibodies |
| DE602004021773D1 (de) | 2004-05-05 | 2009-08-13 | Micromet Ag | Herstellung eines einkettigen fv Antikörperfragments |
| EA013162B1 (ru) * | 2005-04-18 | 2010-02-26 | Микромет Аг | Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека |
| EP1888643B1 (en) | 2005-05-18 | 2014-10-29 | MorphoSys AG | Anti-gm-csf antibodies and uses therefor |
| CN101501070B (zh) | 2006-02-08 | 2013-12-25 | 诺福泰克公司 | 抗原性gm-csf肽和针对gm-csf的抗体 |
-
2006
- 2006-04-18 EA EA200702008A patent/EA013162B1/ru unknown
- 2006-04-18 RS RS20150497A patent/RS54127B1/sr unknown
- 2006-04-18 EP EP12159883A patent/EP2468774A3/en not_active Ceased
- 2006-04-18 WO PCT/EP2006/003528 patent/WO2006111353A2/en not_active Ceased
- 2006-04-18 PL PL06724392T patent/PL1874819T3/pl unknown
- 2006-04-18 PT PT67243923T patent/PT1874819E/pt unknown
- 2006-04-18 ES ES06724392.3T patent/ES2545769T3/es active Active
- 2006-04-18 JP JP2008506992A patent/JP5085533B2/ja active Active
- 2006-04-18 UA UAA200712125A patent/UA94403C2/ru unknown
- 2006-04-18 SG SG201002699-5A patent/SG161292A1/en unknown
- 2006-04-18 CN CN2006800188584A patent/CN101184777B/zh active Active
- 2006-04-18 AU AU2006237159A patent/AU2006237159B2/en active Active
- 2006-04-18 BR BRPI0608281A patent/BRPI0608281B8/pt active IP Right Grant
- 2006-04-18 NZ NZ562093A patent/NZ562093A/en unknown
- 2006-04-18 EP EP06724392.3A patent/EP1874819B1/en active Active
- 2006-04-18 MX MX2007012569A patent/MX2007012569A/es active IP Right Grant
- 2006-04-18 CA CA2605402A patent/CA2605402C/en active Active
- 2006-04-18 US US11/918,368 patent/US8017748B2/en active Active
- 2006-04-18 HR HRP20150773TT patent/HRP20150773T1/hr unknown
- 2006-04-18 KR KR1020157020152A patent/KR20150091193A/ko not_active Abandoned
- 2006-04-18 EA EA200901500A patent/EA017420B9/ru unknown
- 2006-04-18 SI SI200631960T patent/SI1874819T1/sl unknown
- 2006-04-18 RU RU2007138341/10A patent/RU2458071C2/ru active
- 2006-04-18 DK DK06724392.3T patent/DK1874819T3/en active
- 2006-04-18 HU HUE06724392A patent/HUE025134T2/en unknown
- 2006-04-18 ME MEP-2015-111A patent/ME02191B/me unknown
- 2006-04-18 CN CN201310231969.5A patent/CN103342751B/zh active Active
- 2006-04-18 KR KR1020077026929A patent/KR101704809B1/ko active Active
-
2007
- 2007-09-20 ZA ZA200708201A patent/ZA200708201B/en unknown
- 2007-10-08 IL IL186486A patent/IL186486A0/en not_active IP Right Cessation
- 2007-11-12 NO NO20075802A patent/NO344249B1/no unknown
-
2011
- 2011-08-04 US US13/198,558 patent/US9067993B2/en active Active
-
2012
- 2012-04-20 RU RU2012115683/10A patent/RU2012115683A/ru not_active Application Discontinuation
- 2012-06-14 IL IL220412A patent/IL220412A/en active IP Right Grant
-
2015
- 2015-05-21 US US14/718,923 patent/US10138297B2/en active Active
- 2015-08-20 CY CY20151100731T patent/CY1116632T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02191B (me) | Protutijela koja neutraliziraju ljudski čimbenik stimuliranja kolonija makrofaga | |
| ES2902063T3 (es) | Proteínas de unión a interleucina-13 | |
| HRP20130204T1 (hr) | Monoklonalna protutijela koja se vežu na hgm-csf i medicinski sastavi koji ih sadrže | |
| HRP20181085T1 (hr) | Protutijela koja vežu il-4 i/ili il-13 i njihova uporaba | |
| ME02734B (me) | Antitelo koje vezuje il-17a i il-17f | |
| JP2014111644A5 (me) | ||
| JP2009545319A5 (me) | ||
| HRP20192076T1 (hr) | Anti-il-17a protutijela i njihova uporaba u liječenju autoimunih i upalnih poremećaja | |
| HRP20150965T1 (hr) | Anti-fgr3 protutijela i metode koje ih koriste | |
| JP2011518857A5 (me) | ||
| HRP20150937T1 (hr) | Pentaspecifiäśno protutijelo | |
| JP2016128474A5 (me) | ||
| HRP20161069T1 (hr) | Molekule antitijela koje vezuju il-17a i il-17f | |
| HRP20201113T1 (hr) | Vežući proteini protiv lag-3 | |
| HRP20150023T1 (hr) | Protutijela protiv gm-csf i njihova upotreba | |
| HRP20160638T1 (hr) | Antigen vezujući proteini sposobni vezati timusni stromalni limfopoetin | |
| HRP20140512T1 (hr) | Humana antitijela s visokim afinitetom za humani il-4 receptor | |
| JP2008542321A5 (me) | ||
| JP2014519522A5 (me) | ||
| JP2012503979A5 (me) | ||
| RU2007143996A (ru) | Антитела против il2 | |
| HRP20230605T1 (hr) | Protutijela protiv interferona beta i njihova upotreba | |
| JP2020511159A5 (me) | ||
| KR102048475B1 (ko) | IL-17A (Interleukin-17A)에 특이적으로 결합하는 항체 및 이의 용도 | |
| JP2011512120A5 (me) |